Business
InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease
Vancouver, British Columbia--(Newsfile Corp. - October 28, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical
About this update from Inmed Pharmaceuticals Inc.
[{"type":"text","content":"Vancouver, British Columbia--(Newsfile Corp. - October 28, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) (\"InMed\" or the \"Company\"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announced that it has filed an additional international patent application, under the Patent Cooperation Treaty (PCT), focused on the pharmaceutical composition and method of use for the proprietary small molecule drug candidate INM-901 for treating neurodegenerative diseases, including Alzheimer's disease.\nThis PCT patent application encompasses several key components, including:\n\ntreatment of neuronal disorders, particularly those associated with neurodegeneration;\npotential to inhibit or slow the progression of neurodegenerative diseases by reducing cytotoxicity in affected neuron populations; and\nuse in promoting neurite elongation and/or restoring neurite formation in damaged neurons.\n\nAdditionally, the patent application specifies methods for neuroprotection, stimulating neurogenesis, enhancing basal and locomotor activity, improving anxiety-related behaviors, cognitive function, memory, and sound awareness, as well as downregulating inflammation markers and upregulating neuronal function markers.\n\"The INM-901 drug development program represents a novel approach to treating Alzheimer's disease and the conversion of this PCT application is an important step to protect our research and development in the area of neurodegeneration,\" stated Dr. Eric Hsu, Senior Vice President of Preclinical Research & Development at InMed. \"We have recently made significant progress with the INM-901 and are committed to advancing this program towards human clinical trials. We look forward to presenting long-term in vivo data in the coming weeks.\"\nThis development further enhances InMed patent portfolio which currently includes fourteen patent families, eight of which focus on drug composition/formulations/methods of use and six address manufacturing technologies.\nINM-901: Targeting several biological pathways associated with Alzheimer's disease\nINM-901 is a proprietary small molecule drug candidate with multiple mechanisms of action as a potential treatment for Alzheimer's disease. Key characteristics of INM-901 include:\n\ndemonstrates reduced n...